News for Scholar Rock Holding Corporation (SRRK)

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday. Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight […]

Scholar Rock's (SRRK) experimental drug shows promising results, boosting premarket stock by nearly 14%. Analysts forecast a significant upside potentia

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Thursday. Shares of Greif, Inc. GEF rose sharply during Thursday's session after t...

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ETCompany ParticipantsRushmie Nofsinger - VP, Corporate...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atr

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

On December 31, 2024, Eventide Asset Management, LLC executed a significant transaction involving Inozyme Pharma Inc (NASDAQ: INZY). The firm reduced its holdin

Scholar Rock (SRRK) experienced a stock price increase of 2.81% recently, driven by a positive analyst outlook. This performance was noteworthy when compared to

The following slide deck was published by Scholar Rock Holding Corporation in conjunction with their 2024 Q4 earnings call.

Scholar Rock Holding Corporation. (NASDAQ:SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ETCompany ParticipantsJay Backstrom - President...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabol

We recently published a list of 10 Oversold Biotech Stocks to Buy Now.

Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other ...

The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday. Shares of BridgeBio Pharma, Inc. BBIO rose sharply during Monday's se...

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ETCompany ParticipantsJay Backstrom - President...

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?